Reference replicated designs [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2019-09-20 06:35  – Posting: # 20628
Views: 734

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar

Complete thread:

Activity
 Admin contact
20,138 posts in 4,246 threads, 1,387 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 12:11 CET

It is better to debate a question without settling it
than to settle a question without debating it.    Joseph Joubert

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5